Final results of the UK Age trial on breast cancer screening age
Mené en Grande-Bretagne auprès de 160 921 femmes (durée médiane de suivi : 22,8 ans), cet essai estime l'effet d'une mammographie annuelle de dépistage dès l'âge de 40 ans sur la mortalité par cancer du sein
In The Lancet Oncology, the findings from a 23-year follow-up of the UK Age trial are presented by Stephen Duffy and colleagues.1
No difference in mortality from breast cancer was found between the group that began yearly mammography screening at age 39–41 years until they entered the National Health Service (NHS) Breast Screening Programme at age 50–52 years, and a group that did not begin mammography screening until they entered the NHS Breast Screening Programme (126 deaths vs 255 deaths occurring after more than 10 years of follow-up; relative rate 0·98 [95% CI 0·79–1·22]; p=0·86).
The Lancet Oncology , commentaire en libre accès, 2019